Last reviewed · How we verify
ACYC
Acyc works by binding to a specific target in the body, although its exact mechanism is unknown.
Acyc is a small molecule drug developed by Bausch Health Americas, Inc. and currently owned by Ligand Pharmaceuticals. Its target and drug class are unknown, but it has been approved by 48 generic manufacturers, indicating it is off-patent. The commercial status of acyc is unclear, but it is likely available as a generic medication. Key safety considerations are unknown, and further research is needed to understand its effects on patients.
At a glance
| Generic name | ACYC |
|---|---|
| Sponsor | Ligand Pharms |
| Target | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Think of acyc like a key that fits into a lock in the body. When it binds to its target, it can help to either block or activate certain processes, depending on the specific effect it's intended to have. However, without more information about its target and mechanism, it's difficult to say exactly how it works.
Approved indications
- Encephalitis due to Herpesvirus
- Genital herpes simplex
- Herpes labialis
- Herpes simplex
- Herpes simplex infection of skin
- Herpes zoster
- Recurrent Mucocutaneous Herpes Simplex
- Recurrent genital herpes simplex
- Recurrent herpes simplex labialis
- Suppression of Recurrent Herpes Simplex Infection
- Varicella
Common side effects
- Malaise
- Nausea
- Diarrhea
- Nausea and/or vomiting
- Diarrhea
- Headache
- Nausea
- Diarrhea
Serious adverse events
- Stevens-Johnson Syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Encephalopathy
- Renal failure
- Anaphylaxis
- Seizure
- Hepatitis
- Angioedema
- Coma
- Thrombocytopenia
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACYC CI brief — competitive landscape report
- ACYC updates RSS · CI watch RSS
- Ligand Pharms portfolio CI